The work described herein identifies and combines two therapeutic strategies–PPRHs and the small molecule NSC 317605–capable of stabilizing the KRAS promoter G4mid structure, decreasing transcription and synergistically modulating KRAS addicted AsPc-1 pancreatic cancer cells. Here, KRAS is linked to familial pancreatic carcinoma.